JRSIS Health Care Corporation (JRSS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
JRSIS Health Care Corporation (JRSS) with AI Score 35/100 (Weak). JRSIS Health Care Corporation operates Jiarun Hospital in Harbin, China, providing a range of medical services. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026JRSIS Health Care Corporation (JRSS) Healthcare & Pipeline Overview
JRSIS Health Care Corporation, based in Harbin, China, operates Jiarun Hospital, offering diverse medical services such as pediatrics, dermatology, and traditional Chinese medicine. With 950 beds, the hospital serves the Heilongjiang Province. The company faces challenges with negative profitability and operates in a competitive healthcare market.
Investment Thesis
Investing in JRSIS Health Care Corporation presents a high-risk, high-reward scenario. The company operates in the growing Chinese healthcare market but faces significant challenges. Key value drivers include potential expansion of services and increased patient volume at Jiarun Hospital. However, the company's negative profit margin of -47.0% raises concerns about its financial sustainability. Growth catalysts include potential government healthcare reforms and increased demand for medical services in the Heilongjiang Province. The company's ability to improve operational efficiency and reduce costs is crucial for achieving profitability. Potential investors should carefully consider the risks associated with investing in an OTC-listed company with limited financial information and negative earnings. The company's beta of -0.63 suggests a low correlation with the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- JRSIS Health Care Corporation operates Jiarun Hospital, a 950-bed facility in Harbin, China.
- The company offers a wide range of medical services, including pediatrics, dermatology, and traditional Chinese medicine.
- The company's profit margin is -47.0%, indicating significant financial challenges.
- The company's P/E ratio is -0.49, reflecting its negative earnings.
- The company's gross margin is 15.3%.
Competitors & Peers
Strengths
- Comprehensive range of medical services.
- Relatively large hospital capacity (950 beds).
- Established presence in Harbin, Heilongjiang Province.
Weaknesses
- Negative profit margin (-47.0%).
- Limited geographic diversification.
- OTC listing may limit access to capital.
Catalysts
- Ongoing: Potential government healthcare reforms in China could benefit private healthcare providers.
- Upcoming: Expansion of medical services at Jiarun Hospital could attract more patients.
- Ongoing: Increased demand for healthcare services in the Heilongjiang Province due to an aging population.
Risks
- Ongoing: Negative profit margin (-47.0%) raises concerns about financial sustainability.
- Potential: Intense competition from other hospitals and clinics in the region.
- Potential: Regulatory changes impacting healthcare operations in China.
- Potential: Economic downturn affecting patient affordability and demand for services.
- Ongoing: OTC listing and limited financial disclosure increase investment risk.
Growth Opportunities
- Expansion of Medical Services: JRSIS Health Care Corporation can expand its range of medical services to attract more patients and increase revenue. This could involve adding new specialties, such as cardiology or oncology, or investing in advanced medical equipment. The market for specialized medical services in China is growing rapidly, driven by increasing healthcare awareness and rising incomes. Timeline: 2-3 years. Market Size: The Chinese healthcare market is projected to reach $2.3 trillion by 2030.
- Increased Patient Volume: JRSIS Health Care Corporation can increase patient volume at Jiarun Hospital by improving its marketing and outreach efforts. This could involve advertising in local media, partnering with local businesses, and offering discounts and promotions. The demand for medical services in the Heilongjiang Province is growing due to an aging population and increasing urbanization. Timeline: Ongoing. Market Size: The number of hospital visits in China is projected to increase by 5% annually over the next decade.
- Strategic Partnerships: JRSIS Health Care Corporation can form strategic partnerships with other healthcare providers, such as hospitals, clinics, and pharmaceutical companies. This could involve sharing resources, co-marketing services, and developing new products and services. Strategic partnerships can help JRSIS Health Care Corporation expand its reach, improve its efficiency, and enhance its competitiveness. Timeline: 1-2 years. Market Size: The market for healthcare partnerships in China is estimated to be worth $10 billion annually.
- Government Healthcare Reforms: The Chinese government is implementing healthcare reforms to improve access to healthcare and reduce costs. These reforms could create new opportunities for JRSIS Health Care Corporation, such as increased government funding for hospitals and new regulations that favor private healthcare providers. Timeline: Ongoing. Market Size: The Chinese government is investing billions of dollars in healthcare infrastructure and services.
- Telemedicine Integration: JRSIS Health Care Corporation can integrate telemedicine into its operations to reach more patients and improve its efficiency. This could involve offering online consultations, remote monitoring, and virtual care services. The market for telemedicine in China is growing rapidly, driven by increasing internet penetration and the rising demand for convenient healthcare services. Timeline: 1-2 years. Market Size: The Chinese telemedicine market is projected to reach $20 billion by 2025.
Opportunities
- Expanding medical services to meet growing demand.
- Leveraging government healthcare reforms.
- Forming strategic partnerships with other healthcare providers.
Threats
- Intense competition from other hospitals and clinics.
- Regulatory changes impacting healthcare operations.
- Economic downturn affecting patient affordability.
Competitive Advantages
- Established presence in the Heilongjiang Province.
- 950-bed hospital capacity provides a significant infrastructure base.
- Broad range of medical services offers a comprehensive healthcare solution.
About JRSS
Founded in 2006, JRSIS Health Care Corporation, formerly known as China Runteng Medical Group Co., Ltd, is a healthcare provider operating in Harbin, Heilongjiang Province, China. The company's primary asset is Jiarun Hospital, a 950-bed facility offering a broad spectrum of medical services. These services encompass pediatrics, dermatology, ears, nose, throat, traditional Chinese medicine, ophthalmology, internal medicine, dentistry, general surgery, rehabilitation science, gynecology, and general medical services. JRSIS Health Care Corporation aims to provide comprehensive healthcare solutions to the local population. The hospital is equipped to handle a wide range of medical needs, from routine check-ups to specialized treatments. The company changed its name in November 2013, reflecting its commitment to the healthcare sector. The company's operations are concentrated within the Heilongjiang Province, making it a regional player in the Chinese healthcare market. JRSIS Health Care Corporation faces challenges related to profitability, as indicated by its negative profit margin.
What They Do
- Operates Jiarun Hospital, a 950-bed medical facility.
- Provides pediatric medical services.
- Offers dermatological treatments.
- Specializes in ear, nose, and throat care.
- Practices traditional Chinese medicine.
- Provides ophthalmology services.
- Offers internal medicine and dentistry.
- Performs general surgery and rehabilitation science.
Business Model
- Generates revenue through patient fees for medical services.
- Receives payments from insurance companies and government healthcare programs.
- Offers a range of medical specialties to attract a diverse patient base.
Industry Context
JRSIS Health Care Corporation operates within the Chinese healthcare market, which is experiencing significant growth due to an aging population and increasing healthcare awareness. The market is competitive, with both public and private hospitals vying for patients. Key trends include the increasing adoption of telemedicine and the growing demand for specialized medical services. JRSIS Health Care Corporation's position within this market is challenged by its negative profitability and limited geographic reach. Competitors include other healthcare providers in the Heilongjiang Province and national hospital chains.
Key Customers
- Residents of Harbin and the Heilongjiang Province seeking medical care.
- Patients requiring specialized medical treatments.
- Individuals covered by health insurance plans.
Financials
Chart & Info
JRSIS Health Care Corporation (JRSS) stock price: Price data unavailable
Latest News
No recent news available for JRSS.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for JRSS.
Price Targets
Wall Street price target analysis for JRSS.
MoonshotScore
What does this score mean?
The MoonshotScore rates JRSS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Linhai Zhu
CEO
Information on Linhai Zhu's specific background and career history is not available. As the CEO of JRSIS Health Care Corporation, Linhai Zhu is responsible for managing the company's overall operations and strategic direction. The CEO oversees a team of 36 employees and is accountable for the financial performance of Jiarun Hospital. Further details about Linhai Zhu's educational qualifications and previous roles are currently unknown.
Track Record: Due to limited information, it is difficult to assess Linhai Zhu's specific achievements and strategic decisions as CEO. The company's negative profit margin suggests ongoing challenges in achieving profitability. However, without more data, it is impossible to provide a comprehensive evaluation of Linhai Zhu's leadership and impact on the company's performance.
JRSS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that JRSIS Health Care Corporation may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to regular reporting requirements with the SEC, unlike companies listed on major exchanges like the NYSE or NASDAQ. This tier is considered the most speculative due to the lack of stringent listing standards and oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume and liquidity can lead to significant price volatility.
- OTC Other tier companies are subject to less regulatory oversight, increasing the potential for fraud or mismanagement.
- The company's negative profit margin raises concerns about its financial sustainability.
- Potential delisting from the OTC market could further reduce liquidity and value.
- Verify the company's registration and legal standing.
- Attempt to obtain audited financial statements, even if not publicly available.
- Research the background and experience of the company's management team.
- Assess the company's competitive position within the Chinese healthcare market.
- Understand the company's revenue model and cost structure.
- Evaluate the company's ability to improve its financial performance.
- Consult with a qualified financial advisor before investing.
- Operation of a 950-bed hospital suggests a substantial physical presence.
- Provision of a range of medical services indicates a functioning business.
- Company has been in operation since 2006.
JRSS Healthcare Stock FAQ
What does JRSIS Health Care Corporation do?
JRSIS Health Care Corporation operates Jiarun Hospital in Harbin, China, providing a range of medical services to the local population. The hospital offers services in various medical fields, including pediatrics, dermatology, traditional Chinese medicine, and general surgery. With 950 beds, Jiarun Hospital aims to provide comprehensive healthcare solutions to residents of the Heilongjiang Province. The company generates revenue through patient fees and payments from insurance companies and government healthcare programs. The company faces challenges related to profitability and operates in a competitive healthcare market.
What do analysts say about JRSS stock?
There is currently no available analyst coverage or consensus on JRSIS Health Care Corporation (JRSS) due to its OTC listing and limited financial disclosure. Key valuation metrics, such as price targets and earnings estimates, are not available. Investors should conduct their own thorough research and due diligence before considering an investment in JRSS. The company's negative profit margin and limited liquidity raise concerns about its financial performance and investment risk. Potential investors should carefully consider the risks and opportunities associated with investing in an OTC-listed company with limited information.
What are the main risks for JRSS?
The main risks for JRSIS Health Care Corporation include its negative profit margin, which raises concerns about its financial sustainability. The company's OTC listing and limited financial disclosure increase investment risk due to lack of transparency. Intense competition from other hospitals and clinics in the region could impact patient volume and revenue. Regulatory changes impacting healthcare operations in China could also pose a risk. An economic downturn could affect patient affordability and demand for services. Investors should carefully consider these risks before investing in JRSS.
What are the key factors to evaluate for JRSS?
JRSIS Health Care Corporation (JRSS) currently holds an AI score of 35/100, indicating low score. Key strength: Comprehensive range of medical services.. Primary risk to monitor: Ongoing: Negative profit margin (-47.0%) raises concerns about financial sustainability.. This is not financial advice.
How frequently does JRSS data refresh on this page?
JRSS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven JRSS's recent stock price performance?
Recent price movement in JRSIS Health Care Corporation (JRSS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Comprehensive range of medical services.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider JRSS overvalued or undervalued right now?
Determining whether JRSIS Health Care Corporation (JRSS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying JRSS?
Before investing in JRSIS Health Care Corporation (JRSS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be up-to-date or audited.